Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Sarcoma and Rare Cancers Congress 2024

05 Mar 2024

Lugano, Switzerland, 6 March 2024 – The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general. They will provide in-depth perspectives on current and new approaches to research, targeted therapies, precision medicine, methodological challenges, policy and guidelines that touch on the predominant issues and needs in the field. Participation is onsite only.

The scientific and educational programme is available online to help you navigate the richness of sessions.

Programme highlights

  • Novel approaches in the treatment of advanced refractory sarcoma and soft tissue sarcoma.
  • Further evidence on continued treatment with imatinib in patients with localized GIST at high risk of relapse and advanced GIST.
  • New insights into natural history, biology and treatment of rare malignancies.
  • New data confirming impact of rare tumors on health-related quality of life and improvement in quality of life with novel therapies in desmoid tumors.
  • Debate on the centralisation of care in national and international reference networks for rare cancers, access to treatment and clinical trials, the patients’ diagnostic journey and policies.

The results of 149 studies will be presented and published online as a supplement to ESMO Open.

Press accreditation

ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities. To apply for press accreditation, please fill out the form available here. Requests for press accreditation should be sent by Wednesday, 13 March. Please be kindly informed that onsite press accreditation will not be possible.

Further information

ESMO Press Office

Notes to editors

Please make sure to use the official name of the meeting in your reports: ESMO Sarcoma and Rare Cancers Congress 2024 and the official congress hashtag #ESMOSarcomaAndRareCancers24. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Facebook, Instagram, YouTube.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.